2,990 reports of this reaction
1.9% of all DALFAMPRIDINE reports
#15 most reported adverse reaction
MOBILITY DECREASED is the #15 most commonly reported adverse reaction for DALFAMPRIDINE, manufactured by Merz Pharmaceuticals, LLC. There are 2,990 FDA adverse event reports linking DALFAMPRIDINE to MOBILITY DECREASED. This represents approximately 1.9% of all 157,067 adverse event reports for this drug.
Patients taking DALFAMPRIDINE who experience mobility decreased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MOBILITY DECREASED is a less commonly reported adverse event for DALFAMPRIDINE, but still significant enough to appear in the safety profile.
In addition to mobility decreased, the following adverse reactions have been reported for DALFAMPRIDINE:
The following drugs have also been linked to mobility decreased in FDA adverse event reports:
MOBILITY DECREASED has been reported as an adverse event in 2,990 FDA reports for DALFAMPRIDINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MOBILITY DECREASED accounts for approximately 1.9% of all adverse event reports for DALFAMPRIDINE, making it a notable side effect.
If you experience mobility decreased while taking DALFAMPRIDINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.